Inflammatory Bowel Disease Testing Services (2024)

Labcorp's ​DoseASSURE test portfolio provides tests for both drug concentration (TDM) and anti-drug antibody (immunogenicity)

Inflammatory Bowel Disease (IBD) is a chronic disease impacting nearly 1,2 million Americans.1Developments in treatment, such as biologics, have greatly improved quality of life for patients and advancements in laboratory testing are helping to support diagnosis and optimize therapy. Labcorp offers leading expertise and comprehensive testing services to support physicians in the management of IBD patients.

Biologics monitoring assays measure both drug concentration and anti-drug antibodies to support improved clinical outcomes and characterize those patients who may have diminished response to therapy.2, 3, 4, 5

DoseASSURE, Labcorp’s portfolio of biologics monitoring assays, may help physicians optimize biological therapy using a personalized, patient-specific approach.

Patient-specific clinical context must be taken into account when evaluating drug and anti-drug antibody. Serial measurements over time may be helpful.

DoseASSURE patient responsibility summary

Patient responsibility is determined by amount billed to patients after the insurance provider has been billed, including copay, coinsurance, deductible, or coverage denials. Based on managed care claim data** from 2018:

Inflammatory Bowel Disease Testing Services (1)

The Benefits of DoseASSURE

  • All biologics have variable pharmaco*kinetics and the potential to induce an antibody-mediated immune response6,7
  • TDM helps optimize dosing and frequency of treatment2,7,8
  • TDM assists in preventing and managing loss of response due to immunogenicity9,10
  • TDM has been shown to be cost-effective and may direct more appropriate care.7
  • Most comprehensive portfolio of biologics tested:Infliximab, Infliximab-dyyb, Infliximab-abda, Adalimumab, Vedolizumab, Golimumab, Ustekinumab, Certolizumab

Read our Biologics Q&A

  • Number Name
    503870 Infliximab and Anti-Infliximab Antibody, DoseASSURE™ IFX
    503890 Adalimumab and Anti-Adalimumab Antibody, DoseASSURE™ ADL
    504567 Vedolizumab and Anti-Vedolizumab Antibody, DoseASSURE™ VDZ
    504563 Golimumab and Anti-Golimumab Antibody, DoseASSURE™ GOL
    504594 Ustekinumab and Anti-Ustekinumab Antibody, DoseASSURE™ UST
    504627 Certolizumab and Anti-Certolizumab Antibody, DoseASSURE™ CTZ
  • Number Name
    006627 C-Reactive Protein (CRP), Quantitative
    123255 Calprotectin, Fecal
    183988 Clostridioides difficile Toxin Gene, NAA
    005009 Complete Blood Count (CBC) With Differential
    162020 Crohn's Disease Prognostic Profile
    006510 Hepatitis B Surface Antigen (HBsAg) Screen, Qualitative
    016881 Hepatitis B Core Antibody, IgM
    162045 Inflammatory Bowel Disease (IBD) Expanded Profile
    322000 Metabolic Panel (14), Comprehensive
    504104 Methotrexate Polyglutamates
    005215 Sedimentation Rate, Modified Westergren
    008144 Stool Culture
    503800 Thiopurine Metabolites
    510750 Thiopurine Methyltransferase (TPMT), Enzyme Activity, Erythrocytes

** Based on internal Labcorp billing data (2018).

† Includes claims adjudicated as non-covered and for which there was no patient responsibility indicated by the payer. The explanation of benefits (EOB) from the insurance company explains in detail the services that were either paid or denied. If a claim is denied, the patient is responsible for the amount indicated on the EOB the patient receives from the insurer. If further assistance is needed in determining the reason(s) why the insurance company did not pay for testing, patients should contact their insurance carrier directly. A listing of insurance plans billed by Labcorp can be found

Document Downloads & Resources:

  • Labcorp IBD Capabilities Brochure
  • Labcorp IBD Expanded Profile Physician Flyer
  • Labcorp DoseASSURE Flyer
  • Scientific Poster: Analysis - Serum ustekinumab, corresponding anti-ustekinumab antibody patient results

Want to Speak to your Labcorp Representative?

  1. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminariboside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006;131:366-378.

  2. Ferrante M, Liesbet H, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behavior. Gut. 2007;56:1394-1403.

  3. Papp M, Altorjay I, Dotan N et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665-681.

  4. Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel fisease. Clin Vaccine Immunol. 2006;13(6):655-660.

  5. Quinton J-F, Sendid B, Reumaux D, et al. Anti-saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role. Gut. 1998;42:788-791

  6. Malickova K, Lakatos PL, Bortlik M, Komarek V, Janatkova I, Lukas M. Anticarbohydrate antibodies as markers of inflammatory bowel disease in Central European cohort. Eur J Gastroenterol Hepatol. 2010;22(2):144-150.

  7. Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2011 Jun; 17(6): 1428-1435.

  8. Clunie GPR, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatol. 2004 Jan; 43(1):13-18.

  9. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol. 2006 Jan; 1(1):119-128.

  10. IMURAN® (azathioprine) [package insert]. Available at: Accessed: January 27, 2016.

  11. Vande Casteele N, et al. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. Gastroenter 2015;148:1320-1329.

  12. Vaughn BP, et al. Proactive Therapeutic Concentration Monitoring of Infliximab MayImprove Outcomes for Patients with Inflammatory Bowel Disease: Results from a PilotObservational Study. Inflamm Bowel Dis 2014;20:1996-2003.

  13. Vaughn BP, et al. Biologic Concentration Testing in Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:1435-4142.

  14. Ungar B, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014;63:1258-1264.

  15. American Gastroenterological Association. Guidelines for the Identification, Assessmentand Initial Medical Treatment in Crohn’s Disease.

  16. Steenholdt C, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-927.

  17. Ordas, et al. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2012;10:1079-1087.

  18. Steenholdt C, et al. Clinical Implications of Variations in Anti-infliximab Antibody Levels in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2012 Vol 18(12):2209-2217.

Inflammatory Bowel Disease Testing Services (2024)
Top Articles
Latest Posts
Article information

Author: The Hon. Margery Christiansen

Last Updated:

Views: 5725

Rating: 5 / 5 (50 voted)

Reviews: 89% of readers found this page helpful

Author information

Name: The Hon. Margery Christiansen

Birthday: 2000-07-07

Address: 5050 Breitenberg Knoll, New Robert, MI 45409

Phone: +2556892639372

Job: Investor Mining Engineer

Hobby: Sketching, Cosplaying, Glassblowing, Genealogy, Crocheting, Archery, Skateboarding

Introduction: My name is The Hon. Margery Christiansen, I am a bright, adorable, precious, inexpensive, gorgeous, comfortable, happy person who loves writing and wants to share my knowledge and understanding with you.